Maximus Weight Loss Review
From $49.99/mo · Free consult · 4.2★ on Trustpilot · All 50 States
814 verified reviews
Lowest-priced compounded GLP-1 entry in telehealth with microdose option and no-labs-to-start — affordable access path with appropriate clinical-honesty caveats.
Is Maximus the right fit for you?
Who it's for
- Adults with BMI 30+ (or BMI 27+ with weight-related comorbidity) wanting the lowest-priced compounded GLP-1 entry — Maximus Semaglutide microdose at $79.99/mo is below Hims ($199/mo) and competitive across the lowest-tier compounded semaglutide market
- Patients interested in the microdose option specifically — Maximus offers semaglutide microdoses (lower than standard 0.25mg/week starting dose) for patients who want gradual GI-tolerance buildup or sensitivity concerns
- Existing Maximus subscribers on TRT, ED, or hair loss who want weight-loss treatment integrated under the same board-certified prescriber relationship and free-shipping bundled account
- Patients wanting tirzepatide access at competitive pricing — Maximus Tirzepatide microdose at $132/mo is materially cheaper than brand-name Mounjaro/Zepbound cash-pay rates ($1,000+/mo)
Who it's not for
- Anyone with personal or family history of medullary thyroid carcinoma (MTC) or MEN-2 syndrome — these are FDA-labeled contraindications for GLP-1 medications regardless of price tier or provider
- Patients who want comprehensive metabolic baseline labs before starting — Maximus markets "no labs required to start" as a convenience differentiator, but for patients with complex metabolic profiles (suspected insulin resistance, dyslipidemia, inflammatory burden), starting GLP-1 without baseline labs misses information that changes the protocol decision. Marek's comprehensive panel is the appropriate match for those cases
- Anyone uncomfortable with the regulatory uncertainty around compounded GLP-1s post-FDA-shortage-end (early 2026) — the long-term availability of compounded semaglutide and tirzepatide at telehealth pricing is regulatorily uncertain regardless of provider
- Patients wanting brand-name Wegovy, Ozempic, or Mounjaro specifically with insurance billing — Maximus is compounded-only at these price points; insurance-billed brand-name is a different pathway
Your first 3 months with Maximus
Complete the Maximus weight-loss intake — weight history, BMI, medical conditions, GLP-1 contraindications (MTC family history, severe gastroparesis, prior pancreatitis), current medications, target weight, and medication preference (Semaglutide / Tirzepatide / microdose vs full-dose). Free physician consult; the "no labs to start" pathway means same-day prescription approval is possible for low-risk intakes.
First medication shipment lands within 3–5 days of script approval (free priority shipping). For microdose Semaglutide patients: typical start at sub-0.25mg/week dose to build GI tolerance gradually. For standard-dose patients: 0.25mg/week conservative entry. For Tirzepatide patients: 2.5mg/week starting dose or microdose alternative. Side effects (nausea, mild GI upset) peak in the first 2–4 weeks then subside for most patients.
Response and tolerance should be clear. Typical month-1 loss runs 2–5 pounds alongside appetite reduction. The "no labs to start" approach means dose titration decisions in the first month rely on symptom tracking + scale response rather than metabolic markers — workable for straightforward cases but blind to factors that would surface on a comprehensive baseline panel.
Dose titration to therapeutic range (Semaglutide: 0.5mg → 1mg → 1.7mg → 2.4mg/week; Tirzepatide: titration to 5–15mg/week). Average loss at 6 months on therapeutic-dose semaglutide runs 10–15% of starting body weight in responders; tirzepatide responders often see slightly stronger loss. Maximus may recommend labs at this point even though baseline wasn't required — the metabolic markers matter more for long-term protocol decisions than for starting.
Maximus vs the alternatives
[Hims](/online-providers/weight-loss/hims) is the higher-priced mass-market compounded semaglutide at $199/mo (injection format). Maximus undercuts at $79.99/mo Semaglutide microdose and $132/mo Tirzepatide — meaningfully cheaper across both medication options. Maximus's edge: lower entry pricing + microdose option + tirzepatide availability at this price tier + board-certified physicians. Hims's edge: larger operating-history track record (7,800+ Trustpilot reviews vs Maximus's 814+), broader brand recognition. AHF rates Hims 4.0 and Maximus 4.1 (weight-loss) — narrow gap reflects Maximus's pricing advantage offset by Hims's scale advantages.
[PeterMD](/online-providers/weight-loss/petermd) and Maximus both offer multi-medication GLP-1 catalogs (semaglutide + tirzepatide). Maximus undercuts on entry pricing ($79.99/mo Semaglutide microdose vs PeterMD's $200–$300/mo range) and offers the no-labs-to-start convenience pathway. PeterMD's edge: larger operating-history track record (13,000+ Trustpilot reviews vs Maximus's 814+), established brand presence, and the standard pathway requires baseline metabolic labs which adds clinical context for patients who want it. AHF rates PeterMD 4.3 and Maximus 4.1 (weight-loss) — gap reflects PeterMD's track-record depth + standard-labs approach vs Maximus's pricing + no-labs convenience.
Honest Breakdown
What Works Well
- Board-certified physicians specializing in men's health
- Multiple TRT protocols: enclomiphene, injectable, cream, oral
- Competitive GLP-1 pricing starting at $79.99/month
- Innovative dual-compound ED treatment (Tadalafil + Vardenafil)
- At-home lab testing included in protocols
- Free priority shipping on all orders
- 814+ verified Trustpilot reviews
Watch Points
What people actually ask about Maximus
Yes — Maximus operates with board-certified physicians and dispenses compounded GLP-1 medications through 503A/503B compounding pharmacy partners under physician orders. The legitimacy infrastructure clears the basic bar. The 814+ Trustpilot reviews at 4.2 rating include weight-loss-specific feedback. The watch points: post-FDA-shortage-end regulatory uncertainty for compounded GLP-1s (applies equally across all compounded-GLP-1 providers) and the no-labs-to-start convenience trade-off (faster access but less baseline clinical context).
Ready to start with Maximus?
Free consultation. Independently reviewed. Board-certified physicians.
Get Free ConsultationSecure telemedicine · HIPAA compliant · Cancel anytime